Plain-English translation of NCT07167446 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether —a compound derived from hemp—can help prevent nerve damage that sometimes occurs as a side effect of oxaliplatin chemotherapy in people with advanced colorectal cancer. Some patients receiving this chemotherapy experience painful tingling and numbness in their hands and feet. The study will compare patients who take the medication alongside their regular chemotherapy to patients who receive chemotherapy alone, to see if the medication reduces these nerve-related side effects.
Nerve damage from oxaliplatin chemotherapy is a common and sometimes serious side effect that can affect quality of life. Doctors don't yet have an effective way to prevent it, so researchers want to test whether this medication might help protect nerves during treatment.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will either receive the medication (CBD capsules taken by mouth twice daily) or standard chemotherapy alone. If assigned to the medication group, you will start taking capsules the day before your first chemotherapy dose and continue taking them for 7 days after each chemotherapy cycle, with regular check-ins to monitor how you're doing. Throughout the study, you'll have blood tests, nerve exams, and surveys asking about any tingling, numbness, or other side effects. The study lasts as long as you're receiving chemotherapy—typically at least 3 months.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States